Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01776840 · ClinicalTrials.gov registry record · Phase 3
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
A Phase 3 study of Mantle Cell Lymphoma, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 523
- Enrollment target
- 20
- Study locations
NCT01776840 is a Phase 3 study of Mantle Cell Lymphoma that has completed, run by Janssen Research & Development. The registered enrollment target is 523 participants, above the 99-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (428% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT01776840, a Phase 3 study of Mantle Cell Lymphoma, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 523 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ibrutinib given in combination with bendamustine and rituximab in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rituximab
- DRUG Ibrutinib
- DRUG Bendamustine
Study Locations (20)
Illinois
- - Chicago
- - Maywood
- - Niles
- - Springfield
California
- - Burbank
- - La Jolla
- - Stanford
Connecticut
- - New Haven
- - Stamford
Iowa
- - Iowa City
- - Sioux City
Kansas
- - Topeka
- - Westwood
Kentucky
- - Lexington
- - Louisville
Arizona
- - Tucson
Colorado
- - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 523 participants |
| Start Date | 2013-05-16 |
| Est. Completion | 2024-06-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01776840
The ClinicalTrials.gov registry entry for NCT01776840 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 523 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 99-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (428% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01776840 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Illinois, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT01776840 about?
NCT01776840 is a clinical study titled "A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma". The purpose of this study is to evaluate the efficacy and safety of ibrutinib given in combination with bendamustine and rituximab in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.
What is the current status of trial NCT01776840?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 523 participants. The study started on 2013-05-16. Estimated completion is 2024-06-24.
What conditions does trial NCT01776840 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma.
What interventions are being tested in trial NCT01776840?
The interventions under investigation include: Placebo (DRUG), Rituximab (DRUG), Ibrutinib (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT01776840?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01776840 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RECRUITING · Phase 3
-
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
RECRUITING · Phase 3
-
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
COMPLETED · Phase 3
-
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.